Ticker: SOLV

Solventum

Healthcare Healthcare Medical - Care Facilities
Price 78.01
Reco Hold Potential 67 Risk 64 Updated 2026-07-27

Forecast impact

positive
Target +16.6% target fill 85.7%
Reaction D5 +6.80% · D10 +2.17% fresh confirmed · market trust
Impact Potential +6 · Risk -3 valid until 2026-08-12

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Solventum operates in the healthcare sector, focusing on the development and commercialization of innovative medical solutions. Its core products include advanced therapeutic devices and diagnostic tools aimed at improving patient outcomes. The company generates revenue primarily through product sales and partnerships with healthcare providers and institutions. Solventum's business segments encompass research and development, manufacturing, and distribution of healthcare technologies.

Investment Profile

The investment profile of Solventum is more aligned with growth investors, given its focus on innovation and potential for revenue expansion. The company shows stable earnings growth and a moderate risk profile, appealing to those seeking capital appreciation. Its performance metrics suggest a favorable outlook for long-term investment strategies.

Fundamental metrics (experimental) Updated: 2026-07-26
EPS (TTM) — earnings per share for the last 12 months, $
8.21
Revenue QoQ — quarter-over-quarter revenue growth
0.5%
EPS surprise
9.6%
20d volatility
1.5%
AI recommendation changes
Date Before After Reason
2026-07-27 Buy Hold Weak momentum and high risk; cautious outlook advised.
2026-07-19 Hold Buy Positive momentum but uncertain analyst signals.
2026-07-11 Sell Hold Mixed performance; cautious outlook amid sector pressures.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-13 BTIG Target Raised 89 → 91 76.7
2026-07-08 BMO Capital Update — → 81 75.18
2026-06-01 Jefferies Target Raised — → 43 74.95
News Page 1 of 1

Nothing yet